Metformin vs Pancragen
FDA Approved vs Moderate Research
synergistic Mechanism-based · 51% Metformin helps counteract the insulin-disrupting effects of Pancragen. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Metformin Pancragen
Weight 129.16 Da 576 Da
Half-life ~5 hours Not established
Chain — 4 amino acids
Type Biguanide (C4H11N5) Tetrapeptide bioregulator
Key Benefits
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Pancragen
01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors
Dosing Protocols
Metformin
500-2000 mg/day / 1-2x daily with meals
Pancragen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 0.05 mg/kg Daily for 10 days
Side Effects
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Pancragen
Generally well-tolerated
Minimal side effects reported
Contraindications
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)
Research Evidence
Metformin Pancragen
Status FDA Approved Moderate Research
References 5 studies 4 studies
Latest 2023 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.